To contribute to healthy and fulfilling lives for people around the world, improve quality of life, and create a prosperous future, Seikagaku Corporation engages in the manufacturing, research, and development of pharmaceuticals. Ever since its founding, Seikagaku has focused on the importance of glycoscience, creating created innovative pharmaceuticals and medical devices as a pioneer in this emerging field.
 
A key achievement in fiscal 2023, the second year of the mid-term management plan, was the steady advancement of development pipelines. In May 2023, topline results indicating statistically significant improvement in the primary endpoint were obtained in an additional Phase III clinical study in the U.S. for SI-6603, a treatment for lumbar disc herniation. Then, in July 2023, positive results in both the primary endpoint and secondary endpoints were obtained in a pivotal study in Japan of SI-449, an adhesion barrier.
 

In the coming years, Seikagaku will continue to make every effort to ensure a stable supply of truly useful, high-quality products. Also, through our corporate activities, we will conscientiously fulfill our social responsibilities in the areas of sustainability promotion and corporate transparency, fairness, and compliance and contribute to healthy and fulfilling lives for people around the world.
 

We request the continued understanding and support of our shareholders and other stakeholders.

June 2024
 Ken Mizutani
 President & CEO